BACKGROUND: The use of interferon-free direct-acting antiviral agents (DAAs) is associated with a rapid short-term decrease in liver stiffness in chronic hepatitis C-infected patients with sustained virologic response (SVR). OBJECTIVE: The objective of this article is to evaluate long-term changes in liver elasticity in hepatitis C patients with SVR using transient elastography (TE), FIB-4 and APRI. METHODS: A total of 143 patients were treated with DAAs and reached SVR. Patients received TE measurement (median (range)) at treatment start (baseline), follow-up week 24 (FU24) and follow-up week 96 (FU96). Laboratory data were examined at each date and FIB-4 and APRI were calculated. RESULTS: Liver elasticity showed a significant decrease from baseline to FU24 (13.1 (3.1-75) kPa to 9.3 (2.9-69.1) kPa; p < 0.0001) and declined further until FU96 (7.9 (2.4-59.3) kPa; p < 0.0001). Liver inflammation and liver function parameters normalised during long-term follow-up. Progression of liver stiffness between FU24 to FU96 despite viral clearance was observed in 24 patients (17%). Long-term liver stiffness progression was associated with aspartate aminotransferase levels and TE change from baseline to FU24. CONCLUSION: During long-term follow-up, the majority of patients with SVR had further improved liver stiffness values. Still, a significant proportion of patients may show long-term liver stiffness progression and thus continued TE follow-up is recommended.
BACKGROUND: The use of interferon-free direct-acting antiviral agents (DAAs) is associated with a rapid short-term decrease in liver stiffness in chronic hepatitis C-infected patients with sustained virologic response (SVR). OBJECTIVE: The objective of this article is to evaluate long-term changes in liver elasticity in hepatitis C patients with SVR using transient elastography (TE), FIB-4 and APRI. METHODS: A total of 143 patients were treated with DAAs and reached SVR. Patients received TE measurement (median (range)) at treatment start (baseline), follow-up week 24 (FU24) and follow-up week 96 (FU96). Laboratory data were examined at each date and FIB-4 and APRI were calculated. RESULTS: Liver elasticity showed a significant decrease from baseline to FU24 (13.1 (3.1-75) kPa to 9.3 (2.9-69.1) kPa; p < 0.0001) and declined further until FU96 (7.9 (2.4-59.3) kPa; p < 0.0001). Liver inflammation and liver function parameters normalised during long-term follow-up. Progression of liver stiffness between FU24 to FU96 despite viral clearance was observed in 24 patients (17%). Long-term liver stiffness progression was associated with aspartate aminotransferase levels and TE change from baseline to FU24. CONCLUSION: During long-term follow-up, the majority of patients with SVR had further improved liver stiffness values. Still, a significant proportion of patients may show long-term liver stiffness progression and thus continued TE follow-up is recommended.
Authors: Bernhard Schlevogt; Katja Deterding; Kerstin Port; Christoph Höner Zu Siederdissen; Lisa Sollik; Janina Kirschner; Carola Mix; Michael P Manns; Markus Cornberg; Heiner Wedemeyer Journal: Z Gastroenterol Date: 2017-09-12 Impact factor: 2.000
Authors: Adriaan J van der Meer; Raoel Maan; Bart J Veldt; Jordan J Feld; Heiner Wedemeyer; Jean-François Dufour; Frank Lammert; Andres Duarte-Rojo; Michael P Manns; Stefan Zeuzem; W Peter Hofmann; Robert J de Knegt; Bettina E Hansen; Harry LA Janssen Journal: J Gastroenterol Hepatol Date: 2016-06 Impact factor: 4.029
Authors: Swee Lin G Chen Yi Mei; Alexander J Thompson; Britt Christensen; Georgina Cunningham; Lucy McDonald; Sally Bell; David Iser; Tin Nguyen; Paul V Desmond Journal: PLoS One Date: 2017-10-24 Impact factor: 3.240
Authors: Mark S Sulkowski; David F Gardiner; Maribel Rodriguez-Torres; K Rajender Reddy; Tarek Hassanein; Ira Jacobson; Eric Lawitz; Anna S Lok; Federico Hinestrosa; Paul J Thuluvath; Howard Schwartz; David R Nelson; Gregory T Everson; Timothy Eley; Megan Wind-Rotolo; Shu-Pang Huang; Min Gao; Dennis Hernandez; Fiona McPhee; Diane Sherman; Robert Hindes; William Symonds; Claudio Pasquinelli; Dennis M Grasela Journal: N Engl J Med Date: 2014-01-16 Impact factor: 91.245
Authors: Nezam Afdhal; K Rajender Reddy; David R Nelson; Eric Lawitz; Stuart C Gordon; Eugene Schiff; Ronald Nahass; Reem Ghalib; Norman Gitlin; Robert Herring; Jacob Lalezari; Ziad H Younes; Paul J Pockros; Adrian M Di Bisceglie; Sanjeev Arora; G Mani Subramanian; Yanni Zhu; Hadas Dvory-Sobol; Jenny C Yang; Phillip S Pang; William T Symonds; John G McHutchison; Andrew J Muir; Mark Sulkowski; Paul Kwo Journal: N Engl J Med Date: 2014-04-11 Impact factor: 91.245
Authors: Graham R Foster; William L Irving; Michelle C M Cheung; Alex J Walker; Benjamin E Hudson; Suman Verma; John McLauchlan; David J Mutimer; Ashley Brown; William T H Gelson; Douglas C MacDonald; Kosh Agarwal Journal: J Hepatol Date: 2016-01-30 Impact factor: 30.083
Authors: Julia B Balmaceda; Julia Aepfelbacher; Olivia Belliveau; Chloe S Chaudhury; Cheryl Chairez; Mary McLaughlin; Rachel Silk; Chloe Gross; Sarah Kattakuzhy; Elana Rosenthal; Shyam Kottilil; David E Kleiner; Colleen Hadigan Journal: Antivir Ther Date: 2019
Authors: Sergio Ferra-Murcia; Antonio Ramón Collado-Romacho; Bruno José Nievas-Soriano; Fernando Reche-Lorite; Tesifón Parrón-Carreño Journal: J Clin Med Date: 2022-05-07 Impact factor: 4.964
Authors: Carmen González-Corvillo; Isabel Beneyto; Ana Sánchez-Fructuoso; Manel Perelló; Angel Alonso; Auxiliadora Mazuecos; Carlos Jiménez; Sofía Zárraga; Javier Paul; Ricardo Lauzurica; Domingo Hernández; Luis Guirado; Antonio Franco; Juan Carlos Ruiz; Santiago Llorente; Marta Crespo; Alberto Rodríguez-Benot; María Del Carmen de Gracia Guindo; Carmen Díaz-Corte; Miguel Ángel Gentil Journal: Transplant Direct Date: 2019-11-18